In Vivo
>>Market Access

Seres And Ferring Go Head-To-Head In Recurrent C. Difficile Market

Two New Microbiome Medicines Launched In 2023

10 Jul 2023

After the historic approvals of Seres’ and Ferring’s microbiome-based treatments for recurrent Clostridioides difficile infection, the two companies are waiting to see who dominates the $1bn market. Physicians say patients will steer the choice of treatments.

Patients with recurrent C. difficile now have two comparable treatments • Source: Shutterstock

For patients in the US with recurrent Clostridioides difficile infection (rCDI), the recent approval of two safe and effective treatments is a win. Now the question for Seres Therapeutics, Inc. and Ferring Pharmaceuticals is whether either will be able to dominate the market.

Rebyota (fecal microbiota, live – jslm) was approved by the US Food and Drug Administration in November 2022 and Vowst...